跳至主要内容
临床试验/CTRI/2026/01/102334
CTRI/2026/01/102334尚未招募不适用

Efficacy of Satawar (Asparagus racemosus) in enhancing serum AMH levels among women with Diminished ovarian reserve

Dr Umme Aman Saba1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年2月9日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20
试验地点
1

研究概览

简要总结

Diminished Ovarian Reserve (DOR) is a common cause of infertility in women of reproductive age and is characterized by low serum Anti-Müllerian Hormone (AMH) levels. Satawar (Asparagus racemosus) is a classical Unani drug traditionally used to improve female reproductive health and ovarian function.

This study is a prospective, open-label, single-arm interventional clinical trial conducted to evaluate the efficacy of Satawar in improving serum AMH levels among women with Diminished Ovarian Reserve. Twenty women aged 20–40 years with serum AMH levels less than 1.0 ng/mL will be enrolled after obtaining written informed consent.

Participants will receive oral Safoof-e-Satawar at a dose of 6 g/day (3 g twice daily) with lukewarm milk for a period of 90 days. The primary outcome measure is change in serum AMH levels assessed at baseline and at Day 90. Secondary outcomes include assessment of menstrual regularity, antral follicle count, ovarian volume, and safety of the intervention.

The study aims to provide clinical evidence for the role of Satawar in improving ovarian reserve in women with Diminished Ovarian Reserve.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
20.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • Female patients aged between 20 and 40 years.
  • Serum amh levels below 1.0 ng/mL.
  • Regular menstrual cycle or oligo/irregular cycles.
  • Patients with Amenorrhea.
  • Infertile patients.
  • Willing to participate and sign the written informed consent.
  • Fit to take oral Unani medications for the duration of the study.

排除标准

  • Known systemic disorders such as tuberculosis, or malignancy.
  • Menopause women’s.
  • Women with comorbidities.
  • Patients undergoing assisted reproductive technologies (ART) concurrently.
  • Pregnant or lactating women.
  • Hypersensitivity to the drug Administration.

研究者

发起方
Dr Umme Aman Saba
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Umme Aman Saba

Government Nizamia Tibbi College And General Hospital

研究点 (1)

Loading locations...

相似试验